[HTML][HTML] Combination Use of First-Line Afatinib and Proton-Pump Inhibitors Reduces Overall Survival Among Patients with EGFFR Mutant Lung Cancer
MC Ho, YS Chung, YC Lin, MS Hung… - OncoTargets and …, 2022 - ncbi.nlm.nih.gov
Purpose Previous retrospective studies reported that proton-pump inhibitors (PPIs) may
decrease the efficacy of first-generation epidermal growth factor receptor tyrosine kinase …
decrease the efficacy of first-generation epidermal growth factor receptor tyrosine kinase …
Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study
TH Kim, JH Choi, MS Ahn, HW Lee, SY Kang, YW Choi… - BMC cancer, 2024 - Springer
Background Both first and second-generation EGFR-TKIs are recommended in advanced
NSCLC with common EGFR mutations. However, there are few data on the difference in …
NSCLC with common EGFR mutations. However, there are few data on the difference in …